ZA201105665B - Methods for increasing endogenous plasmalogen levels - Google Patents

Methods for increasing endogenous plasmalogen levels

Info

Publication number
ZA201105665B
ZA201105665B ZA2011/05665A ZA201105665A ZA201105665B ZA 201105665 B ZA201105665 B ZA 201105665B ZA 2011/05665 A ZA2011/05665 A ZA 2011/05665A ZA 201105665 A ZA201105665 A ZA 201105665A ZA 201105665 B ZA201105665 B ZA 201105665B
Authority
ZA
South Africa
Prior art keywords
methods
increasing endogenous
plasmalogen levels
endogenous plasmalogen
levels
Prior art date
Application number
ZA2011/05665A
Other languages
English (en)
Inventor
Frederic Destaillats
Fabiola Dionisi
Jean-Baptiste Bezelgues
Cristina Cruz-Hernandez
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of ZA201105665B publication Critical patent/ZA201105665B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Feed For Specific Animals (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
ZA2011/05665A 2009-01-02 2011-08-01 Methods for increasing endogenous plasmalogen levels ZA201105665B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20417009P 2009-01-02 2009-01-02
PCT/US2009/006749 WO2010077358A1 (en) 2009-01-02 2009-12-30 Methods for increasing endogenous plasmalogen levels

Publications (1)

Publication Number Publication Date
ZA201105665B true ZA201105665B (en) 2013-01-30

Family

ID=42310073

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/05665A ZA201105665B (en) 2009-01-02 2011-08-01 Methods for increasing endogenous plasmalogen levels

Country Status (10)

Country Link
US (1) US20110275600A1 (https=)
EP (1) EP2373161A4 (https=)
JP (1) JP2012514597A (https=)
CN (1) CN102271502A (https=)
AU (1) AU2009333809A1 (https=)
CA (1) CA2747582A1 (https=)
MX (1) MX2011007188A (https=)
RU (1) RU2011132386A (https=)
WO (1) WO2010077358A1 (https=)
ZA (1) ZA201105665B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010100060A2 (en) * 2009-03-04 2010-09-10 Nestec S.A. Method for increasing endogenous plasmalogen levels in mammals
CN103314291B (zh) * 2010-12-28 2016-05-11 藤野脑研究株式会社 通过血液样品判定痴呆症用的检验方法
JP5934483B2 (ja) * 2011-09-05 2016-06-15 学校法人帝京大学 リン脂質結合型ｄｈａ増加剤
JP5997887B2 (ja) * 2011-09-05 2016-09-28 学校法人帝京大学 経口投与剤
JP7704407B2 (ja) * 2021-08-04 2025-07-08 株式会社 レオロジー機能食品研究所 がん治療用組成物
JP2023108631A (ja) * 2022-01-26 2023-08-07 大道 藤本 ドッグフード

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US8052992B2 (en) * 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
US20080033027A1 (en) * 2005-03-21 2008-02-07 Vicus Therapeutics Spe 1, Llc Drug combination pharmaceutical compositions and methods for using them
US20080044487A1 (en) * 2006-05-05 2008-02-21 Natural Asa Anti-inflammatory properties of marine lipid compositions
JP5220842B2 (ja) * 2007-04-13 2013-06-26 フェノメノーム ディスカバリーズ インク プラスマロゲン欠乏症が媒介する加齢に伴う疾患の診断及びリスク評価のための方法

Also Published As

Publication number Publication date
WO2010077358A1 (en) 2010-07-08
CN102271502A (zh) 2011-12-07
RU2011132386A (ru) 2013-02-10
US20110275600A1 (en) 2011-11-10
MX2011007188A (es) 2011-09-01
EP2373161A4 (en) 2012-05-30
EP2373161A1 (en) 2011-10-12
JP2012514597A (ja) 2012-06-28
AU2009333809A1 (en) 2011-07-14
CA2747582A1 (en) 2010-07-08

Similar Documents

Publication Publication Date Title
GB2489836B (en) Level
GB0909292D0 (en) Ion tunnelion guide
GB2541819B (en) Box level
EP2429850A4 (en) USE FOR AN OPENING
EP2526744A4 (en) ENHANCED BIOMARKER GENERATOR
GB201117661D0 (en) Early entry
GB0921329D0 (en) Biomarker
ZA201105665B (en) Methods for increasing endogenous plasmalogen levels
GB2482933B (en) An improved shoe
GB201004442D0 (en) Biomarker
GB201005561D0 (en) Biomarkers
GB0915750D0 (en) An air-brick
GB201001444D0 (en) Biomarkers
GB201301684D0 (en) Early entry
GB201001963D0 (en) Fixing insert
GB201005456D0 (en) Biomarkers
IL217333A0 (en) Biomarker
EP2588088A4 (en) SOLID SHAPES
GB0912175D0 (en) Biomarker
GB201120098D0 (en) Early entry
GB201001419D0 (en) Biomarkers
GB201104990D0 (en) Screw-fix level
TWM390298U (en) Improved structure for housing
PL117921U1 (pl) Wkładka mocująca
GB201007919D0 (en) Biomarker